This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nakagawa, M. Articles by Moscicki, A.-B. Search for Related Content PubMed PubMed Citation Articles by Nakagawa, M. Articles by Moscicki, A.-B.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, July 2002, p. 877-882, Vol. 9, No. 4
1071-412X/02/$04.00+0     DOI: 10.1128/CDLI.9.4.877-882.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women

Departments of Laboratory Medicine,¹ Pediatrics,³ Stomatology, Schools of Medicine and Dentistry, University of California at San Francisco, San Francisco, California,⁴ Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, Maryland²

Received 27 November 2001/ Returned for modification 11 February 2002/ Accepted 18 March 2002

The time course of cell-mediated and humoral immune responses was elucidated in eight women with human papillomavirus type 16 (HPV-16) infection by performing serial HPV-16 E6 and E7 cytotoxic T-lymphocyte (CTL) assays and HPV-16 virus-like particle (VLP) antibody analyses. Four subjects had a single incident of HPV-16 DNA detection, and four subjects had two periods of HPV-16 DNA detection. In two of the women in the latter group, the second episode of HPV-16 detection occurred in the presence of high titers of HPV-16 VLP antibody, bringing into question the protective role of humoral immunity in preventing repeated infection. However, all four subjects rapidly became HPV-16 DNA negative following the second detection of HPV-16 DNA, suggesting the presence of immunological memory. In addition, one subject rapidly became negative for HPV-16 DNA despite having no evidence of CTL or VLP antibody response prior to the second HPV-16 DNA detection, suggesting the presence of immunological responses at an undetectable level. Overall, seven of eight subjects (88%) had detectable HPV-16 E6 and/or E7 CTL responses and seven of eight women (88%) had detectable HPV-16 VLP antibody responses.